Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results

F. Chiesa, N. Tradati, M. Marazza, N. Rossi, P. Boracchi, L. Mariani, M. Clerici, F. Formelli, L. Barzan, A. Carrassi, A. Pastorini, T. Camerini, R. Giardini, S. Zurrida, F. L. Minn, A. Costa, G. De Palo, U. Veronesi

Research output: Contribution to journalArticlepeer-review

Abstract

This paper analyses preliminary results of a randomised chemoprevention trial in patients surgically treated for oral leukoplakia started in 1988 at the Istituto Nazionale Tumori of Milan with the synthetic retinoid N-(4-hydroxyphenyl)-retinamide (4-HPR). To date 115 patients have been randomised, after surgical excision of oral leukoplakia, to receive 200 mg 4-HPR daily for 52 weeks versus no intervention. 80 patients completed the 1-year intervention, 41 in the control group and 39 in the 4-HPR group. During this period 12 local relapses or new lesions occurred in the control group and three in the 4-HPR group. Only 5 patients interrupted the intervention because of toxicity. No impaired dark adaptation was observed. It is concluded that 4-HPR is well tolerated and seems efficacious in preventing relapses and new localisations during the treatment period. This promising trend needs further confirmation.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalEuropean Journal of Cancer. Part B: Oral Oncology
Volume28
Issue number2
DOIs
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results'. Together they form a unique fingerprint.

Cite this